Loading…
Artelo Biosciences, Inc. is projected to rise to $0.8892 by 2027, a +20% move from its current price of $0.7427. ARTL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.7013 | $0.7429 | $0.787 | +0.03% |
| Aug 6 | $0.685 | $0.7432 | $0.8063 | +0.07% |
| Aug 7 | $0.6728 | $0.7434 | $0.8215 | +0.10% |
| Aug 8 | $0.6627 | $0.7437 | $0.8346 | +0.13% |
| Aug 9 | $0.6539 | $0.7439 | $0.8463 | +0.17% |
| Aug 10 | $0.6462 | $0.7442 | $0.8571 | +0.20% |
| Aug 11 | $0.6391 | $0.7444 | $0.8671 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6391 | $0.7444 | $0.8671 | +0.23% |
| Week 2 | $0.6014 | $0.7461 | $0.9258 | +0.46% |
| Week 3 | $0.5742 | $0.7479 | $0.974 | +0.70% |
| Week 4 | $0.5525 | $0.7496 | $1.02 | +0.93% |
| Week 5 | $0.5342 | $0.7513 | $1.06 | +1.16% |
| Week 6 | $0.5183 | $0.7531 | $1.09 | +1.40% |
| Week 7 | $0.5042 | $0.7548 | $1.13 | +1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company that develops and commercializes therapeutics that target lipid-signaling pathways in the United States. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, Depression, PTSD, epilepsy and insomnia, and other potential indications.
It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc.
in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Artelo Biosciences, Inc. (ARTL) is a clinical stage biopharmaceutical company focused on therapeutics that target lipid-signaling pathways in the United States. The stock trades with a current price of $0.7234 and a market cap of $2.52M, holding a rank of 5416.
The current price sits within a forecast range that shows variability over time, with the long-run outlook turning bullish in several future years. The forecast implies an upward trajectory in average prices from $0.7234 in 2026 to $2.67 in 2050, with notable upper-bound opportunities in specific years.
A major floor 48.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 69.7% above — a clean break opens room to run.
A major ceiling 1319.1% above — clearing it would confirm fresh momentum.
Key ARTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8276 | Sell | $0.8255 | Sell |
| MA 10 | $0.9528 | Sell | $0.9084 | Sell |
| MA 20 | $1.02 | Sell | $1.01 | Sell |
| MA 50 | $1.19 | Sell | $1.49 | Sell |
| MA 100 | $2.96 | Sell | $2.70 | Sell |
| MA 200 | $4.31 | Sell | $5.89 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 25.81 | Buy |
| Stoch RSI (14) | 24.51 | Neutral |
| CCI (20) | -167.28 | Sell |
| Williams %R (14) | -89.24 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -33.04 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 10.76 | Buy |
| TRIX (15) | -1.30 | Sell |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 18.69 | Buy |
| Momentum (10) | -0.38 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 0.69 | Buy |
| ADX (14) | 36.80 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 20, indicating relatively oversold conditions. The 50-day simple moving average sits at $1.22, while the 200-day simple moving average stands at $4.43.
Support is listed at $0.723 and resistance at $1.29. The 30-day price range spans from $0.4871 to $1.07, showing a tight window around the current price and a neutral near-term tendency.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.723 | $0.7427 | $0.9243 | 0% | Neutral | |
| $0.6479 | $0.8892 | $1.32 | +20% | Neutral | |
| $0.8416 | $1.23 | $1.94 | +65% | Bullish | |
| $0.705 | $1.08 | $1.80 | +46% | Bullish | |
| $0.6534 | $1.05 | $1.82 | +42% | Bullish | |
| $0.6058 | $1.02 | $1.83 | +38% | Bullish | |
| $0.4753 | $0.8359 | $1.55 | +13% | Neutral | |
| $0.5692 | $1.04 | $1.98 | +40% | Bullish | |
| $0.6426 | $1.22 | $2.39 | +65% | Bullish | |
| $0.6717 | $1.33 | $2.65 | +79% | Bullish | |
| $0.6007 | $1.33 | $2.93 | +80% | Bullish | |
| $1.22 | $2.72 | $6.26 | +266% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.723 | $0.7427 | $0.8643 | +0.00% |
| September 2026 | $0.5861 | $0.7124 | $0.9034 | -4.08% |
| October 2026 | $0.621 | $0.7654 | $0.9905 | +7.45% |
| November 2026 | $0.5893 | $0.7347 | $0.9662 | -4.02% |
| December 2026 | $0.5499 | $0.6927 | $0.9243 | -5.70% |
Click any year to see its month-by-month ARTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ARTL could reach as high as $0.9243, with a base case around $0.7427 and support toward $0.723 — roughly 0% from $0.7427. Price action looks broadly range-bound.
Expect ARTL to range from $0.6479 to $1.32 through 2027. The $0.8892 average target implies a +20% move from current prices. That is up +20% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ARTL price prediction for 2028 points to an average of $1.23 (low $0.8416, high $1.94) — a potential gain of +65% on today's $0.7427. Momentum favours further upside here.
In 2029, ARTL is projected to trade between $0.705 and $1.80, averaging $1.08 — a potential gain of +46% from today's $0.7427. That is -12% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Artelo Biosciences, Inc.'s 2030 outlook centres on $1.05, within a $0.6534 to $1.82 range. That is -3% versus the projected 2029 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2031, ARTL could reach as high as $1.83, with a base case around $1.02 and support toward $0.6058 — roughly +38% from $0.7427. Buyers look set to stay in control over this stretch.
Expect ARTL to range from $0.4753 to $1.55 through 2032. The $0.8359 average target implies a +13% move from current prices. That is -18% versus the projected 2031 average. Price action looks broadly range-bound.
The ARTL price prediction for 2033 points to an average of $1.04 (low $0.5692, high $1.98) — a potential gain of +40% on today's $0.7427. Buyers look set to stay in control over this stretch.
In 2034, ARTL is projected to trade between $0.6426 and $2.39, averaging $1.22 — a potential gain of +65% from today's $0.7427. That is up +17% on the projected 2033 average. Momentum favours further upside here.
Artelo Biosciences, Inc.'s 2035 outlook centres on $1.33, within a $0.6717 to $2.65 range. That is up +9% on the projected 2034 average. That marks a +79% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ARTL could reach as high as $2.93, with a base case around $1.33 and support toward $0.6007 — roughly +80% from $0.7427. Momentum favours further upside here.
Expect ARTL to range from $1.22 to $6.26 through 2050. The $2.72 average target implies a +266% move from current prices. That is up +104% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARTL today (≈ 1,346.43867 ARTL) could be worth
$3,663.88
+$2,663.88 (+266%) by 2050 · US Dollar
Based on the average projected ARTL price of $2.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARTLwould be worth at today's price.
$1,000 invested in ARTL on Jul 31, 2025 (≈ 28.105676 ARTL) would be worth
$20.87
-$979.13 (-97.9%) today · 0.02× · US Dollar
Based on a ARTL entry price of $35.58 vs. today's $0.7427.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.02 | $728.14 | -27.2% |
| 1 month ago | $1.1 | $675.18 | -32.5% |
| 3 months ago | $3.39 | $219.09 | -78.1% |
| 6 months ago | $4.89 | $151.88 | -84.8% |
| 1 year ago | $35.58 | $20.87 | -97.9% |
| All time (5.0y) ago | $253.8 | $2.93 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARTL forecast.
Our base-case forecast reaches $1.50 around 2050.
Implied market cap at $1.50: $5.23M
Over the multi-year forecast, Artelo shows a bullish tilt in several horizon years. The 2026 forecast lists a min of $0.723, avg $0.7234, max $0.9064 with ROI 0% and NEUTRAL sentiment. The 2027 forecast points to an avg of $0.8793, max $1.31, min $0.6402 with ROI 21.6% and BULLISH sentiment.
The 2028 forecast shows avg $1.19 with a max of $1.88 and ROI 64.4%. In 2029 the avg is $1.06 and the max is $1.76 (ROI 46.1%). For 2030 the avg is $1.03 with a min $0.6377 and max $1.78 (ROI 42.3%, BULLISH).
2031 yields avg $0.9878, min $0.5856, max $1.77 (ROI 36.5%). 2032 shows a lower avg $0.8194 with a neutral stance and a max of $1.52 (ROI 13.3%). 2033’s avg is $1.02 with a max $1.94 (ROI 41.1%).
2034’s avg is $1.19 and max $2.31 (ROI 63.9%). 2035’s avg is $1.30 and max $2.60 (ROI 80.1%). 2040’s forecast has an avg of $1.29 and a max of $2.83 (ROI 78.4%). The 2050 forecast shows min $1.20, avg $2.67, max $6.13 with ROI 268.7% and a BULLISH sentiment.
These figures illustrate a long-run ascent with higher upside potential in later years, but with periods of moderation or pullbacks along the way. Note that volatility is high, as indicated by an annualized volatility of 100%.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $1.03 with a min of $0.6377 and a max of $1.78, and an ROI of 42.3%; sentiment is BULLISH.
Forecasts show bullish sentiment in several future years (e.g., 2027 avg $0.8793 and 2050 avg $2.67 with ROI 268.7%), but there are years with more modest upside (e.g., 2026 ROI 0% and 2032 ROI 13.3%). These are estimates and not guarantees.
Yes. The max prices in multiple years exceed $1: 2027 max $1.31, 2028 max $1.88, 2033 max $1.94, 2034 max $2.31, 2040 max $2.83, and 2050 max $6.13.
Current price is $0.7234 and market cap is $2.52M.
For 2050 the min is $1.20, avg $2.67, max $6.13, ROI 268.7; sentiment is BULLISH.
Artelo Biosciences, Inc. Community Discussion
0Share your Artelo Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.